Ipsen’s Cabometyx + Opdivo Receive EC’s Approval as a 1L Treatment for Patients with Advanced Renal Cell Carcinoma

 Ipsen’s Cabometyx + Opdivo Receive EC’s Approval as a 1L Treatment for Patients with Advanced Renal Cell Carcinoma

Ipsen’s Cabometyx + Opdivo Receive EC’s Approval as a 1L Treatment for Patients with Advanced Renal Cell Carcinoma

Shots:

  • The approval is based on P-III CheckMate -9ER trial involves assessing Cabometyx + Opdivo vs sunitinib in 651 patients with previously untreated advanced/m-RCC
  • The results demonstrated significant improvement across all efficacy EPs. The trial met its 1EPs i.e. showed doubled mPFS (16.6 vs 8.3mos.); ORR (55.7% vs. 27.1%); CR (8.0% vs 4.6%); OS (40% reduction in risk of death), improvement in DCR with a lower rate of discontinuation, consistent efficacy benefits observed across key subgroups of patients and was well tolerated
  • The approval allows for the marketing of combination regimen in all 27 member states of the EU, Norway, Liechtenstein, and Iceland

Click here to­ read full press release/ article | Ref: Business Wire | Image: Business Wire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post